Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc. has raised the probability of approval for its product RP1 in combination with Opdivo for advanced melanoma to 95%, reflecting strong clinical efficacy evidenced by an objective response rate of approximately 33.6%. The company's ability to scale in-house manufacturing to meet global supply demands contributes positively to its cost of goods sold and overall financial outlook. Furthermore, the initiation of the IGNYTE-3 confirmatory trial with plans to enroll over 100 global sites indicates a robust pipeline and potential for commercial success in the near future.

Bears say

Replimune Group Inc. is facing a negative financial outlook, primarily due to a projected net loss of $2.99 per share for fiscal 2025, which indicates deteriorating financial performance compared to earlier estimates of $2.93 per share. The company is also confronted with significant risks including potential failure to generate effective clinical trial data for its lead candidate, RP1, as well as challenges in obtaining regulatory approval and delivering on its early-stage pipeline. Additionally, concerns regarding possible safety signals and the potential for medium- to long-term dilution create further pressure on Replimune's stock prospects.

REPL has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 13 analysts, REPL has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.